Lifecore Biomedical (LFCR) to Release Earnings on Thursday

Key Points

• Lifecore Biomedical will report quarterly results after the market close on April 2, with analysts forecasting earnings of ($0.27) per share and revenue of about $25.96 million.
• The company recently missed EPS estimates (reported ($0.16) vs. estimate ($0.11)) and shows severe profitability pressure—a negative return on equity (1,211.09%) and a net margin of -23.08%—with analysts forecasting roughly -$1 EPS for the current and next fiscal years.
• Shares have a market capitalization near $145 million and a one‑year range of $3.86–$8.98; the consensus analyst rating is Hold with a $5.50 average price target and about 83% institutional ownership.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) will likely be announcing its results after the market closes on Thursday, April 2nd. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $25.9570 million for the quarter.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last posted its quarterly earnings results on Monday, March 16th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.05). The company had revenue of $35.75 million for the quarter, compared to the consensus estimate of $35.31 million. Lifecore Biomedical had a negative return on equity of 1,211.09% and a negative net margin of 23.08%. On average, analysts expect Lifecore Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lifecore Biomedical Price Performance

Shares of Lifecore Biomedical stock opened at $3.87 on Friday. The company has a debt-to-equity ratio of 113.76, a current ratio of 2.80 and a quick ratio of 1.67. Lifecore Biomedical has a one year low of $3.86 and a one year high of $8.98. The business's 50 day simple moving average is $6.95 and its two-hundred day simple moving average is $7.29. The stock has a market capitalization of $145.05 million, a P/E ratio of -3.95 and a beta of 0.62.

Institutional Investors Weigh In On Lifecore Biomedical

A number of large investors have recently made changes to their positions in LFCR. Quarry LP bought a new position in shares of Lifecore Biomedical during the third quarter valued at approximately $28,000. BNP Paribas Financial Markets boosted its holdings in Lifecore Biomedical by 92.7% in the third quarter. BNP Paribas Financial Markets now owns 5,791 shares of the company's stock valued at $43,000 after acquiring an additional 2,786 shares in the last quarter. State of Wyoming bought a new stake in Lifecore Biomedical in the second quarter valued at $69,000. The Manufacturers Life Insurance Company purchased a new position in Lifecore Biomedical during the 2nd quarter valued at $88,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Lifecore Biomedical by 14.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company's stock valued at $104,000 after purchasing an additional 1,886 shares during the period. 83.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on LFCR shares. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Lifecore Biomedical in a research note on Thursday, January 22nd. Barrington Research reissued an "outperform" rating and set a $5.50 price target on shares of Lifecore Biomedical in a research report on Tuesday. Finally, Zacks Research raised shares of Lifecore Biomedical to a "hold" rating in a report on Thursday, January 1st. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Lifecore Biomedical has an average rating of "Hold" and a consensus target price of $5.50.

About Lifecore Biomedical

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.